Browsing by Author "Ayhan, Figen"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP(Springer Heidelberg, 2012-01) Bodur, Hatice; Ataman, Şebnem; Buğdaycı, Derya Soy; Rezvani, Aylin; Nas, Kemal; Uzunca, Kaan; Emlakçıoğlu, Emel; Karatepe, Altınay Göksel; Durmuş, Bekir; Sezgin, Melek; Ayhan, Figen; Yazgan, Pelin; Duruöz, Tuncay; Yener, Mahmut; Gürğan, Alev; Kırnap, Mehmet; Çakar, Engin; Soydemir, Raikan; Çapkın, Erhan; Tekeoğlu, İbrahim; Aydın, Gülümser; Günendi, Zafer; Nacır, Barış; Şallı, Ali; Öztürk, Cihat; Memiş, Asuman; Turan, Yasemin; Kozanoğlu, Erkan; Sivrioğlu, Konçuy; Altan, Lale; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-1652-2021; 6603281363A web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 +/- A 10.7 years). Mean disease duration was 12.1 +/- A 8.5 years, and mean time from initial symptom to diagnosis was 5 +/- A 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was a parts per thousand yen4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses.Publication Turkish compliance and adaptation of EULAR 2013 recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: Expert opinion of TLAR(Turkish League Against Rheumatism, 2015-05-27) Ataman, Şebnem; Sürmeli, Zühre Sarı; Sunar, İsmihan; Özdemirel, Erhan; Akıncı, Ayşen; Bodur, Hatice; Akgul, Ozgur; Altan, Lale; Altay, Zuhal; Ayhan, Figen; Birtane, Murat; Soy Buğdaycı, Derya; Capkin, Erhan; Cerrahoglu, Lale; Duruoz, Mehmet Tuncay; Gunaydin, Rezzan; Gunendi, Zafer; Gurer, Gulcan; Bal, Ajda; Kacar, Cahit; Kaptanoglu, Ece; Kaya, Taciser; Kocabas, Hilal; Kotevoglu, Nurdan; Nas, Kemal; Rezvani, Aylin; Sen, Nesrin; Sendur, Omer Faruk; Yalcin, Peyman; ALTAN İNCEOĞLU, LALE; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; AAH-1652-2021Objectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey.Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected.Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same.Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.